KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of Deferred ChargesAmortization of GoodwillAmortization of GoodwillAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Amortization of Deferred Charges (2023 - 2026)

Pacira BioSciences has reported Amortization of Deferred Charges over the past 4 years, most recently at $577000.0 for Q1 2026.

  • For Q1 2026, Amortization of Deferred Charges fell 31.72% year-over-year to $577000.0; the TTM value through Mar 2026 reached $2.7 million, down 19.4%, while the annual FY2025 figure was $3.0 million, 6.98% down from the prior year.
  • Amortization of Deferred Charges for Q1 2026 was $577000.0 at Pacira BioSciences, down from $677000.0 in the prior quarter.
  • Over five years, Amortization of Deferred Charges peaked at $1.4 million in Q4 2023 and troughed at $577000.0 in Q1 2026.
  • A 4-year average of $811076.9 and a median of $763000.0 in 2024 define the central range for Amortization of Deferred Charges.
  • Biggest five-year swings in Amortization of Deferred Charges: crashed 34.73% in 2024 and later grew 24.08% in 2025.
  • Year by year, Amortization of Deferred Charges stood at $1.4 million in 2023, then tumbled by 34.73% to $938000.0 in 2024, then dropped by 27.83% to $677000.0 in 2025, then fell by 14.77% to $577000.0 in 2026.
  • Business Quant data shows Amortization of Deferred Charges for PCRX at $577000.0 in Q1 2026, $677000.0 in Q4 2025, and $626000.0 in Q3 2025.